SecBot SecBot
Institutional Cluster

BBIO

BridgeBio Pharma, Inc.
MIXED
Impact 6/10
Horizonmonths Processed2mo ago
Institutional cluster: 33 buyers, 25 sellers (mixed)
Actionable Insight ◆ Mixed

The active-quant buying cluster (D.E. Shaw, Jane Street, RenTech, Point72, Bridgewater) is a strong signal that sophisticated investors are positioning for the upcoming PDUFA catalysts (BBP-418 Nov 2026, encaleret May 2027). The passive selling is likely index-rebalancing noise. Monitor for any insider buying to corroborate the thesis, current insider activity shows 7 sells in the last 30 days with no open-market buys, which is a divergence. The $1B preferred equity financing provides a cash runway through these catalysts.

DirectionMixed
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$81.07
T+0 close · Aug 22, 2026 · via day close
Latest settled
−14.60%
T+20 · $69.23 · next T+60 in 12h
Vs SPY
−15.92%
α at T+20
Latest observation
+4.80%
T+57 · FF3 residual α
  1. T+0 · Aug 24 $81.07entry
  2. T+1 · 3mo ago −0.83%α −1.15% · $80.40
  3. T+5 · 3mo ago −5.53%α −6.00% · $76.59
  4. T+20 · 8w ago −14.60%α −15.92% · $69.23
  5. T+59 · todayOpen
  6. T+60 · in 12h Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma saw a mixed institutional cluster in Q2 2026, with 33 buyers adding $561.6M in net new positions (led by Norges Bank, Point72, and D.E. Shaw) while 25 sellers trimmed $218.2M (led by Geode and Northern Trust). The buying is concentrated among active quant and asset managers (D.E. Shaw, Jane Street, RenTech, Point72) likely positioning ahead of key PDUFA catalysts (BBP-418 Nov 2026, encaleret May 2027) and the $1B preferred equity financing, while the selling is dominated by mega-passive index funds (Geode, T. Rowe Price) trimming for rebalancing. The divergence between active buyers and passive sellers, combined with the strong Q2 revenue growth ($243.7M, more than doubling YoY) and the recent $1B capital raise, suggests conviction in the pipeline catalysts outweighs the EPS miss and ongoing operating losses.

Key Financial Metrics

Direction
mixed
Buy Value
$1.1B
Net Flow
$343.4M

Institutional Positions

Net institutional flow: $343.4M

▲ Buyers (33)

InstitutionActionChangePosition ValueValue Δ
Norges BankNEW+100%$126.2M$126.2M
Point72NEW+100%$113.6M$113.6M
D.E. ShawADD+42.7%$270.6M$81.6M
Jane Street GroupADD+66.9%$218.5M$88.0M
RenTechDOUBLED+134.3%$63.8M$36.7M

▼ Sellers (25)

InstitutionActionChangePrev ValueValue Δ
GeodeTRIM-30.5%$371.9M-$117.3M
Northern TrustTRIM-31.6%$104.2M-$32.8M
American Century CompaniesTRIM-43%$81.0M-$34.7M
Walleye CapitalNEAR_EXIT-99.3%$17.0M-$16.9M
T. Rowe PriceTRIM-54.6%$282.0K-$153.7K

Key Facts

  • 33 institutional buyers added $561.6M in net new positions in Q2 2026
  • 25 institutional sellers trimmed $218.2M, led by mega-passive index funds
  • Norges Bank initiated a new $126.2M position; Point72 initiated $113.6M
  • D.E. Shaw added $81.6M (+42.7%), Jane Street added $88.0M (+66.9%)
  • Geode trimmed $117.3M (-30.5%), Northern Trust trimmed $32.8M (-31.6%)
  • Q2 2026 revenue $243.7M (more than doubled YoY) but EPS missed consensus ($0.78 actual vs $0.64 consensus)
  • Key catalysts: BBP-418 PDUFA Nov 27, 2026; encaleret PDUFA May 8, 2027
  • $1B preferred equity financing completed post-quarter

Financial Impact

Net institutional buying of $561.6M by 33 buyers vs $218.2M selling by 25 sellers, for a net inflow of approximately $343.4M in Q2 2026

institutional ownershipfloatvaluation

Risk Factors

  • EPS miss of $0.78 vs $0.64 consensus indicates ongoing profitability challenges
  • No insider open-market buying to corroborate the institutional thesis
  • PDUFA catalysts are binary events with significant downside risk on failure
  • 13F data is 45+ days stale; positions may have been adjusted since quarter-end

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-BBIO-2026-Q2

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (14h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 22, 2026